$RANI News

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

Rani Therapeutics to Participate in the Chardan Healthcare Conference

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

Rani Therapeutics Joins FDA Emerging Technology Platform

Rani Therapeutics to Participate in Upcoming September Conferences

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Rani Therapeutics Reports Initial Phase 1 Data Showing Oral RT‑114 Delivered Systemic Exposure Exceeding Matched Subcutaneous Administration, With Safety And Tolerability Consistent With GLP‑1/GLP‑2 Agonist Class

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Rani Therapeutics Partners With PegBio To Mull Delivery Of Multiple Novel Candidates From PegBio's Obesity And Metabolic Disease Pipeline Through RaniPill Platform

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

Rani Therapeutics Prices ~$20M Offering Of 12.48M Common Shares At $1.07/Share

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

Rani Therapeutics Hldgs Q1 EPS $(0.04), Inline, Sales $1.708M Beat $500.000K Estimate